Literature DB >> 26202638

Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity.

Blaire E Burman1, Paul Y Kwo2, Kris V Kowdley3.   

Abstract

Entities:  

Keywords:  Direct-acting antivirals; Hepatitis C

Year:  2014        PMID： 26202638     DOI： 10.1007/s12072-014-9552-6

Source DB:  PubMed          Journal:  Hepatol Int        ISSN： 1936-0533            Impact factor:   9.029


× No keyword cloud information.
  77 in total

1.  Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.

Authors:  John G McHutchison; Eric J Lawitz; Mitchell L Shiffman; Andrew J Muir; Greg W Galler; Jonathan McCone; Lisa M Nyberg; William M Lee; Reem H Ghalib; Eugene R Schiff; Joseph S Galati; Bruce R Bacon; Mitchell N Davis; Pabak Mukhopadhyay; Kenneth Koury; Stephanie Noviello; Lisa D Pedicone; Clifford A Brass; Janice K Albrecht; Mark S Sulkowski
Journal:  N Engl J Med       Date:  2009-07-22       Impact factor: 91.245

Review 2.  The role of resistance in HCV treatment.

Authors:  Johannes Vermehren; Christoph Sarrazin
Journal:  Best Pract Res Clin Gastroenterol       Date:  2012-08       Impact factor: 3.043

Review 3.  Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3.

Authors:  E B Tapper; N H Afdhal
Journal:  J Viral Hepat       Date:  2013-10       Impact factor: 3.728

4.  Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy.

Authors:  Y Shiratori; F Imazeki; M Moriyama; M Yano; Y Arakawa; O Yokosuka; T Kuroki; S Nishiguchi; M Sata; G Yamada; S Fujiyama; H Yoshida; M Omata
Journal:  Ann Intern Med       Date:  2000-04-04       Impact factor: 25.391

Review 5.  Review and management of drug interactions with boceprevir and telaprevir.

Authors:  Jennifer J Kiser; James R Burton; Peter L Anderson; Gregory T Everson
Journal:  Hepatology       Date:  2012-05       Impact factor: 17.425

Review 6.  Directly acting antivirals for the treatment of chronic hepatitis C: unresolved topics from registration trials.

Authors:  Alessio Aghemo; Elisabetta Degasperi; Massimo Colombo
Journal:  Dig Liver Dis       Date:  2012-06-12       Impact factor: 4.088

7.  Baseline hepatitis C virus (HCV) NS3 polymorphisms and their impact on treatment response in clinical studies of the HCV NS3 protease inhibitor faldaprevir.

Authors:  Kristi L Berger; Ibtissem Triki; Mireille Cartier; Martin Marquis; Marie-Josée Massariol; Wulf O Böcher; Yakov Datsenko; Gerhard Steinmann; Joseph Scherer; Jerry O Stern; George Kukolj
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

8.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors:  Stefan Zeuzem; Ira M Jacobson; Tolga Baykal; Rui T Marinho; Fred Poordad; Marc Bourlière; Mark S Sulkowski; Heiner Wedemeyer; Edward Tam; Paul Desmond; Donald M Jensen; Adrian M Di Bisceglie; Peter Varunok; Tarek Hassanein; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

Review 9.  Interleukin-28B and fibrosing cholestatic hepatitis in posttransplant hepatitis C: a case-control study and literature review.

Authors:  Andres Duarte-Rojo; Vikram Budhraja; Bart J Veldt; David D Goldstein; Kymberly D Watt; Julie K Heimbach; John G McHutchison; Hans L Tillman; John J Poterucha; Michael R Charlton
Journal:  Liver Transpl       Date:  2013-12       Impact factor: 5.799

Review 10.  Antiviral strategies in hepatitis C virus infection.

Authors:  Christoph Sarrazin; Christophe Hézode; Stefan Zeuzem; Jean-Michel Pawlotsky
Journal:  J Hepatol       Date:  2012       Impact factor: 25.083
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.